Halozyme Therapeutics, Inc. (NasdaqGS:HALO) is looking for M&A. Nicole LaBrosse, Chief Financial Officer said, "We've planned for up to $100 million of repurchases in 2023 and then also continue to explore opportunities to grow the M&A".